Dalbavancin as an option for treatment of S. aureus bacteremia (DOTS): study protocol for a phase 2b, multicenter, randomized, open-label clinical trial

Overview of attention for article published in Trials, May 2022

Altmetric Badge

Mentioned by

twitter: 15 X users

Citations

dimensions_citation: 24 Dimensions

Readers on

mendeley: 28 Mendeley

Summary X Dimensions citations

So far, Dimensions has found 24 publications that cite this research output.

24

The most recent citing publications are shown below. View all 24 publications that cite this research output on Dimensions.

Combination of Antistaphylococcal β-Lactam With Standard Therapy Compared to Standard Therapy Alone for the Treatment of Methicillin-Resistant Staphylococcus aureus Bacteremia: A Post Hoc Analysis of the CAMERA2 Trial Using a Desirability of Outcome Ranking Approach

Article in Open Forum Infectious Diseases (April 2024)

Real-World Dalbavancin Use for Serious Gram-Positive Infections: Comparing Outcomes Between People Who Use and Do Not Use Drugs

Article in Open Forum Infectious Diseases (March 2024)

Finding value in novel antibiotics: How can infectious diseases adopt incremental cost-effectiveness to improve new antibiotic utilization?

Article in Diagnostic Microbiology and Infectious Disease (March 2024)

This page shows the most recent citations of this research output.

Click here to find out how to access more activity.